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Abstract
Background: The tetracyclic triterpene euphol is the main constituent found in the sap of Euphorbia tirucalli. This plant is
widely known in Brazilian traditional medicine for its use in the treatment of several kinds of cancer, including leukaemia,
prostate and breast cancers. Here, we investigated the effect of euphol on experimental models of colitis and the
underlying mechanisms involved in its action.
Methodology/Principal Findings: Colitis was induced in mice either with dextran sulfate sodium (DSS) or with 2,4,6-
trinitrobenzene sulfonic acid (TNBS), and the effect of euphol (3, 10 and 30 mg/kg) on colonic injury was assessed. Pro-
inflammatory mediators and cytokines were measured by immunohistochemistry, enzyme-Linked immunoabsorbent assay
(ELISA), real time-polymerase chain reaction (RT-PCR) and flow cytometry. Preventive and therapeutic oral administration of
euphol attenuated both DSS- and TNBS-induced acute colitis as observed by a significant reduction of the disease activity
index (DAI), histological/microscopic damage score and myeloperoxidase (MPO) activity in colonic tissue. Likewise, euphol
treatment also inhibited colon tissue levels and expression of IL-1b, CXCL1/KC, MCP-1, MIP-2, TNF-a and IL-6, while reducing
NOS2, VEGF and Ki67 expression in colonic tissue. This action seems to be likely associated with inhibition of activation of
nuclear factor-kB (NF-kB). In addition, euphol decreased LPS-induced MCP-1, TNF-a, IL-6 and IFN-c, but increased IL-10
secretion from bone marrow-derived macrophages in vitro. Of note, euphol, at the same schedule of treatment, markedly
inhibited both selectin (P- and E-selectin) and integrin (ICAM-1, VCAM-1 and LFA-1) expression in colonic tissue.
Conclusions/Significance: Together, these results clearly demonstrated that orally-administered euphol, both preventive or
therapeutic treatment were effective in reducing the severity of colitis in two models of chemically-induced mouse colitis
and suggest this plant-derived compound might be a potential molecule in the management of inflammatory bowel
diseases.
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Introduction
Inflammatory bowel diseases (IBD) are a group of chronic
disease that affect the gastrointestinal tract and have been mainly
subdivided as ulcerative colitis (UC) and Crohn’s disease (CD).
Although its etiopathogenesis has not been definitively elucidated,
it is currently considered an abnormal inflammatory response to
intestinal microbial flora. However, there is still not consensus
whether or not IBD should be considered as an autoimmunity,
since the loss of tolerance is towards gut microbiota and the
autoantigen in the human body is still missing [1]. IBD is now
considered as a result of continuous microbial antigenic stimula-
tion of pathogenic immune responses as a consequence of host
genetic defects in mucosal barrier function, innate bacterial killing
or immunoregulation [2].
CD is characterized by TH type-1 response, marked by up-
regulation of interferon-c (IFN- c), a key cytokine, which mainly
driven T cells. On the other hand, UC appears to exhibit an
contribution of TH2 responses (characterized by secretion of
interleukin (IL)-4 and IL-13), which driven NK-T cells [3],
although this difference in immune response is not yet well
established. Interestingly, it was observed that in both CD and UC
some pro-inflammatory mediators such as tumour necrosis factor-
a (TNF-a), IL-6 and IL-1b are released in inflamed mucosa.
It is now well recognized that inflammation of the intestinal
mucosa is characterized by chronic inflammatory cell infiltration
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accompanied by production of pro-inflammatory cytokines, like
IL-1b, IL-6, TNF-a and IFN-c [4]. In addition, the recruitment of
these cells from the vasculature to sites of inflammation is
dependent on a multistep cascade of adhesive interactions, which
are mediated by adhesion molecules and chemoattractants, such
as, integrins/selectins and chemokines, respectively [5,6].
Over the past decade, a substantial amount of evidence has
been generated to support a crucial role of leukocytes in the
pathogenesis of colitis [7,8]. The process of leukocyte extravasa-
tions is a critical step in the inflammatory response and is
dependent on three different families {Barreiro, #603}. (1)
Selectins belong to a family of three carbohydrate-recognizing
molecules: E-selectin, which is mainly expressed on activated
endothelium; P-selectin, which is expressed on platelets and the
endothelium; and L-selectin, which is constitutively expressed on
leukocytes [10]. Several studies using antibody blockade of
selectins have demonstrated the relevant role of selectins in
leukocyte rolling [11,12]. (2) Integrins comprise a family of 24
heterodimeric receptors, each of which is composed of an a- and a
b-subunit. These molecules dynamically alter their adhesive
properties through conformational changes (affinity) as well as
through spatial redistribution on the cell surface and are
fundamental molecules in cell migration [13,14]. Furthermore,
integrins can recognize multiple ligands including proteins of the
extracellular matrix, cell surface glycoprotein as well as comple-
ment factors and soluble components of the hemostatic and
fibrinolytic cascade. (3) The major integrin ligands involved in
leukocyte adhesion belong to the immunoglobulin superfamily
[15] and include intercellular cell adhesion molecules (ICAM) 1–5,
vascular cell adhesion molecule-1 (VCAM-1) and junctional
adhesion molecules (JAMs), which are expressed on endothelial
and other types of cells [16]. Thus, blocking adhesion molecules
constitutes a potential and useful target for controlling leukocyte
influx into the site of inflammation and consequently, leads to the
development of new anti-inflammatory drugs.
The tetracyclic triterpene euphol (Fig.1A) is the main constit-
uent found in the sap of Euphorbia tirucalli, a plant belonging to the
family Euphorbiaceae, and known in Brazilian traditional
medicine as aveloz, a ´rvore-do-la ´pis, cega-olho or espinho-italiano.
In the northeast region of Brazil, the latex of E. tirucalli is used as a
folk therapy against syphilis, laxative agent, to control intestinal
parasites, to treat asthma, cough, earache, rheumatism, cancer,
chancre, epithelioma, sarcoma and skin tumors [17]. The bark/
latex of E. tirucalli presents pharmacological activities as mollus-
cicide, antiherpetic and anti-mutagenic [17]. It also shows co-
carcinogenic and anti-carcinogenic activities [18]. In addition, the
sap of E. tirucalli showed relevant potential larvicide against Aedes
aegypti and Culex quinquefasciatus, the most common dengue vector
and lymphatic filariasis vector, respectively [19] and demonstrated
Figure 1. Euphol ameliorates DSS-induced acute colitis. (A), Chemical structure of euphol. Mice received DSS for 5 days and drinking water for
the next 2 days. Animals were orally treated by gavage with 3, 10, or 30 mg/kg of euphol twice a day from day 0 to day 7 (preventive treatment) or
with 30 mg/kg from day 3 to day 7 (therapeutic treatment). Preventive or therapeutic oral treatment with euphol improved the disease activity index
(DAI) score (B), reduced body weight loss (C) and colon macroscopic damage (D), and enhanced colon length (E) when compared with mice from the
DSS group. Data are reported as means 6 S.E.M. of 8 to 10 mice per group and is representative of three independent experiments.
#P,0.05 vs.
control healthy group; *P,0.05 vs. DSS-treated group.
doi:10.1371/journal.pone.0027122.g001
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pesticides, organophosphates and pyrethroids for the fish Hetero-
pneustes fossilis [20]. Furthermore, a very recent study demonstrated
that biopolymeric fraction (BET) from plant E. tirucalli showed
dose dependent anti-arthritic activity and demonstrated in vivo
suppression of CD4
+ and CD8
+ T cells associated with inhibition
of intracellular IL-2 and IFN-c [21]. Our group has previously
shown that euphol administered orally elicited pronounced and
long-lasting analgesia when assessed in several rodent behavior
models of inflammatory and neuropathic persistent pain and these
actions were likely to be associated with the inhibition of TNF-a
and IL-1b levels, as well as inhibition of transcription factors, such
as nuclear factor-kB (NF-kB) and cyclic AMP response element-
binding protein (CREB), both in the spinal cord and dorsal root
ganglia (unpublished data).
Despite great progress observed over the previous decades in
understanding the cellular and molecular mechanisms involved in
IBD, few effective and safe drugs have emerged to treat acute and
chronic inflammatory bowel states. Therefore, new effective
treatment for IBD is urgently needed. Hence, in the present
study, we investigated the preventive and therapeutic potential
effects of euphol in dextran sulfate sodium (DSS)- and 2,4,6-
trinitrobenzene sulfonic acid (TNBS)-induced colonic inflamma-
tion in mice. Herein, we report that the tetracyclic triterpene
euphol can effectively ameliorate DSS- and TNBS-induced colitis
by inhibiting pro-inflammatory mediators such as cytokines/
chemokines in the colonic tissue and in primary cultures of
macrophages in vitro. Our data also indicated that the mechanisms
underlying the anti-inflammatory activity of euphol was likely to
be related with its ability to inhibit selectin and integrin expression
in the endothelium, associated with the blocking of nitric oxide
synthase-2 (NOS2), vascular endothelial growth factor (VEGF),
and Ki67 expression in colonic tissue by modulating the nuclear
transcription factor-kB (NF-kB).
Results
Euphol treatment attenuates the severity of DSS-induced
acute colitis
In mice with DSS-induced acute colitis, which resembles the
acute phase of human ulcerative colitis, we observed hemorrhage
in the colonic lumen, body weight loss and marked diarrhea with
bloody stools, which ultimately resulted in a sharp increase of the
disease activity index (DAI) from day 3 onwards, compared with
control healthy (non-colitic) mice (Fig. 1). Euphol was adminis-
tered orally at three different doses (3, 10 and 30 mg/kg) to detect
potential dose-dependent effects. Preventive oral treatment with
30 mg/kg of euphol but not with 3 or 10 mg/kg significantly
reduced the DAI from day 3 onwards (Fig. 1B). DSS administra-
tion was associated with significant body weight loss on days 5, 6
and 7. Mice treated with euphol (30 mg/kg) were protected from
marked body weight loss and recovered a healthy appearance that
was similar to that of control healthy mice (non-colitic) (Fig. 1C).
DSS administration resulted in colon inflammation associated with
hyperemia, ulceration and bowel wall thickening, leading to an
increase in macroscopic colon damage and decrease in colon
length (Fig. 1 D,E). Oral euphol (30 mg/kg) treatment reduced
macroscopic damage (Fig. 1D) and significantly prevented colon
length reduction (Fig. 1E) on the 7
th day after colitis induction. In
contrast, treatment with euphol at doses of 3 or 10 mg/kg, p.o.,
was not able to reduce macroscopic damage, prevent colon length
reduction and recover the loss in body weight. Based on these
results, the dose of 30 mg/kg of euphol was used in subsequent
experiments to investigate some of the mechanisms underlying its
anti-inflammatory effects.
Next, we determined whether euphol also had a therapeutic
effect on DSS-induced acute colitis by administering it after colitis
symptoms were seen on day 3, since although preventive
treatments are important, treatments that have efficacy after
colitis symptoms have been established are more clinically
relevant. The results for the disease activity index (Fig. 1B), body
weight loss (Fig. 1C), macroscopic damage (Fig. 1D) and colon
length (Fig. 1E) showed that the therapeutic effect of euphol
(30 mg/kg, p.o.) was as effective as its preventive effect in
alleviating the severity of DSS-induced acute colitis.
Euphol treatment inhibited polymorphonuclear leukocyte influx
and reduced colon damage
Several studies have suggested that tissue damage and
inflammatory signals in experimental colitis are mainly mediated
by polymorphonuclear leukocytes (PMN), mainly neutrophils
[6,8]. We therefore assessed whether the effect of euphol treatment
in DSS-mediated colitis was associated with alterations in the
composition of the neutrophil population in the intestinal mucosa.
Seven days after the initiation of DSS treatment, mucosal
neutrophils infiltration into the colon was indirectly assessed by
measuring MPO activity. Colonic samples taken from untreated
(DSS) mice displayed significantly increased MPO levels relative to
control healthy mice (non-colitic) (Fig. 2A). Notably, preventive
oral treatment with euphol at 10 and 30 mg/kg, but not 3 mg/kg,
significantly reduced DSS-induced increase in colonic MPO levels
(Fig. 2A). Of note, therapeutic treatment with euphol (30 mg/kg,
p.o.) also inhibited MPO levels (Fig. 2A). To further investigate the
effect of euphol treatment in the architecture and integrity of
colonic structure and confirm results from MPO analysis, colons
were processed for histological observation. Mice with colitis
induced by DSS exhibited disruption of the epithelial barrier, a
marked decrease in the number of crypts, and marked infiltration
of inflammatory cells, predominantly neutrophils, into the mucosa
and sub mucosa of the colon, corroborating the MPO assay
(Fig. 2B). The histological evaluation of colons from euphol-
treated (30 mg/kg, p.o.) mice revealed a pronounced reduction in
the inflammatory response with moderate loss of epithelial cells
and minimal inflammatory infiltration into the colonic tissue,
resulting in a decreased microscopic damage score, compared with
colons from DSS mice (untreated) (Fig. 2 B,C).
Euphol prevents epithelial surface lesion in colonic tissue
Next, we assessed whether euphol treatment could restore the
morphological characteristics of inflamed colonic mucosa follow-
ing DSS administration using scanning electron microscopy (SEM)
[22]. SEM observations of the colonic mucosa in control healthy
mice showed a normal epithelium with crypts and some
granulated mast cells. The mucosal surface appeared to be
subdivided by well-defined concave grooves and regular-shaped
crypt openings containing mucin like material. A regular
microvillus carpet makes the epithelial surface smooth and velvety
(Fig. 2D). The DSS-group showed degenerated epithelium, severe
inflammatory cell infiltration, widened grooves, dilatations of
glandular crypts losing their regular shape by assuming fissure like
aspects and depletion of goblet cells, leaving an irregular craterlike
area (Fig. 2D). Relevantly, treatment with euphol (30 mg/kg, p.o.)
following 7 days of DSS treatment significantly restored the
architecture of the colon epithelium with a marked decrease in
inflammatory cell infiltration compared with the DSS group
(untreated mice). Similar to the control healthy group (non colitic),
euphol treatment restored the microvillus carpet and made the
epithelial surface smooth (Fig. 2D).
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during experimental ulcerative colitis
It has been shown that selective blockade of IL-1R, CXCR2,
CXCL1/KC, MCP-1, MIP-2, TNF-a and IL-6 significantly
decreases severity of colitis and neutrophil/macrophage migration
[4,6,23]. In this set of experiments, we investigated whether oral
treatment with euphol could inhibit the levels and expression of
pro-inflammatory cytokines/chemokine in the colonic tissues.
Colonic levels of the pro-inflammatory cytokines IL-1b, CXCL1/
KC, MIP-2 and MCP-1 were markedly elevated 7 days after the
initiation of DSS treatment (Fig. 3 A–D). Preventive treatment
with euphol (30 mg/kg, p.o.) significantly inhibited the levels of
IL-1b by 80% (Fig. 3A), KC by 48% (Fig. 3B), MIP-2 by 65%
(Fig. 3C) and MCP-1 by 80% (Fig. 3D) in colon tissue (P,0.05). In
addition, DSS administration resulted in a pronounced increase in
colonic IL-1b, CXCL1/KC, TNF-a and IL-6 mRNA expression
(Fig. 3 E–H). Interestingly, euphol treatment (30 mg/kg), given
orally during 7 day following DSS administration, significantly
inhibited the up-regulated mRNA expression of IL-1b by 95%
(Fig. 3E), CXCL1/KC by 100% (Fig. 3F), TNF-a by 40%
(Fig. 3G) and IL-6 by 75% (Fig. 3H) (P,0.05). Such data suggest
that the anti-inflammatory action of euphol is likely to be
associated with its abilities to inhibit the release and expression
of cytokines/chemokines as well as inhibit neutrophils influx into
colonic tissue after DSS administration.
Euphol reduces cytokine release from LPS-stimulated
macrophages
The reduction in IL-1b, CXCL1/KC, MCP-1 and MIP-2 levels
induced by euphol in DSS-treated colon could be just a
consequence of decreased cellular adhesion or migration; inflam-
matory cells produce cytokines and chemokines, thus a decrease in
the presence of these cells could also correspond to a decrease in
their secreted cytokines/chemokines. To clarify whether euphol
could also diminish the production of inflammatory mediators or
modify the profile of cytokines produced by the inflammatory cells
present in colonic tissue after inflammatory stimulus, we cultured
primary bone marrow-derived macrophages and evaluated the
influence of euphol on MCP-1, TNF-a, IL-6, IFN-c and IL-10
production after in vitro stimulation with LPS (1 mg/ml, for 24 h), an
Figure 2. Treatment with euphol reduces cell influx and microscopic colon damage after DSS-induced acute colitis. At 7 days after
euphol oral treatment, colon tissues were processed for histological evaluation, measurement of myeloperoxidase (MPO) activity and scanning
electron microscopy. Preventive (3, 10, and 30 mg/kg, p.o.) or therapeutic (30 mg/kg, p.o.) treatment with euphol reduced MPO (A) activity. (B)
Representative histological sections of colon from control healthy mice (non colitic), DSS-treated and euphol-treated mice (30 mg/kg, p.o.) were
examined microscopically after H&E staining with original magnification x20. The images are representative of at least four mice per group. (C)
Preventive treatment with euphol (30 mg/kg, p.o.) decreased the microscopic damage score in mouse colon. (D) Scanning electron microscopy
photographs of the colon of the colon surfaces of control healthy mice, DSS-treated group, and DSS plus euphol (30 mg/kg, p.o.) treated mice after 7
days following DSS administration. Original magnification: x750 and x6,000, respectively. Each column represents the mean 6 S.E.M. of 8 to 10 mice
per group and is representative of two independent experiments.
#P,0.05 vs. control healthy group (non colitic); *P,0.05 vs. DSS-treated group.
doi:10.1371/journal.pone.0027122.g002
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phages stimulated with LPS for 24 h increased MCP-1, TNF-a,I L -
6 and IFN-c levels (Fig. 4 A–E). In vitro pre-treatment (30 min) with
euphol (1 and 10 mM) markedly blocked MCP-1, TNF-a, IL-6 and
IFN-c levels after LPS administration (Fig. 4). In addition, LPS
administration decrease IL-10 levels and, interestingly, euphol (1
and 10 mM) increased IL-10 production in the macrophage culture
after LPS administration (Fig. 4E).
Euphol inhibits NOS2 and VEGF expression induced by
DSS
Ulcerative colitis appears to be caused by a disruption of
intestinal homeostasis and integrity, while up-regulated NOS2
expression in gut mucosa has been shown to cause apoptosis of
epithelial cells [24]. Furthermore, it has been suggested that NOS2
is also involved in angiogenesis [25] a relevant phenomenon that
has recently been demonstrated to be one of the major
contributors to the pathogenesis of IBD [26]. Our present data
corroborated with this observation by demonstrating that DSS-
induced colitis increased NOS2 (Fig. 5 A,C) and VEGF expression
(Fig. 5 B,D). Interestingly, preventive treatment with euphol
(30 mg/kg) significantly blocked the increase in NOS2 and VEGF
expression in colonic tissue (Fig. 5).
Euphol inhibits inflammatory and enterocyte cells
proliferation during inflammation bowel induced by DSS
Ki-67 is a nuclear protein necessary for cell proliferation and is
expected to play a central role in the inflammatory process [27].
To explore whether or not euphol could interfere with
inflammatory and enterocyte cells proliferation we evaluated Ki-
67 staining in colon tissue after DSS administration. Tissue
sections from control mice exhibited very low levels of specific
staining for Ki-67 in epithelial cells (Fig. 6). In contrast, at 7 days
after DSS administration, the untreated (DSS) group showed
intense immunostaining for Ki67 expression in colon tissue,
mainly in the inflammatory cells, but also in enterocyte cells (Fig. 6
A,C). On the other hand, the preventive oral treatment with
euphol (30 mg/kg, twice a day) during 7 days following DSS
administration, significantly inhibited proliferation index in colon
tissue, using monoclonal antibodies against ki67 (Fig. 6 A,C).
Euphol prevents colonic NF-kB activation in the colon
tissue after DSS administration
The transcriptional factor NF-kB is among the major pro-
inflammatory signaling pathways involved in colitis [28,29].
Herein, in order to further evaluate the possible mechanisms
involved in the anti-inflammatory action of euphol, we next
assessed whether the oral pre-treatment with euphol was able to
decrease the activation of transcriptional factors NF-kB, in the
colonic tissue after DSS administration. As shown in Fig. 6, low
levels of NF-kB p65 was detected in the naive mouse colon;
however, DSS-induced inflammation bowel, as expected, lead to a
pronounced phosphorylation of p65 NF-kB in the colonic tissue
after 7 days (Fig. 6 B,D). Interestingly, the pre-treatment with
euphol (30 mg/kg, p.o.), significantly reduced the p65 NF-kB
activation in the mouse colon tissue, thus strongly suggesting that
inhibition of NF-kB activation seems to be the key mechanism
Figure 3. Preventive treatment with euphol changes colonic protein levels and mRNA expression of inflammatory mediators. At the
end of 7 days, colon tissue was collected and processed for cytokine levels and mRNA expression. (A–D) Enzyme-linked immunosorbent assay.
Preventive treatment with euphol (30 mg/kg, p.o.) reduced colonic levels of interleukin-1b (IL-1b) (A), keratinocyte-derived chemokine (CXCL1/KC)
(B), macrophage inflammatory protein-2 (MIP-2) (C) and monocyte chemoattractant protein-1 (MCP-1) (D). (E–H) Real-time PCR. The same scheme of
treatment with euphol also impaired the increase colonic mRNA expression of IL-1b (E), CXCL1/KC (F), tumor necrosis factor-a (TNF-a) (G) and
interleukin-6 (IL-6) (H). The real-time PCR assay was performed in duplicate and GAPDH mRNA was used to normalize the relative amount of mRNA.
Data are reported as means 6 S.E.M. of 8 to 10 mice per group and is representative of three independent experiments.
#P,0.05 vs. control healthy
group (non colitic); *P,0.05 vs. DSS-treated group.
doi:10.1371/journal.pone.0027122.g003
Euphol and Experimental Colitis
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(Fig. 6 B,D).
Anti-inflammatory effect of euphol is mediated by
inhibition of adhesion molecule expression in colonic
tissue
The process of leukocyte extravasations, a critical step in the
inflammatory response, involves migration of leukocytes from the
bloodstream toward colon tissue, which is orchestrated by the
combined actions of cellular adhesion receptors (selectins and
integrins) and chemotactic factors {Barreiro, #603}. In this set of
experiments, we assessed whether oral treatment with euphol was
able to decrease the expression of adhesion molecules in colonic
tissue. In the first set of experiments, we assessed mRNA
expression of adhesion molecules on day 7 after the induction of
colitis. In the DSS group (untreated), a pronounced increase in
colonic ICAM-1 (Fig. 7A), VCAM-1 (Fig. 7B) and LFA-1 (Fig. 7C)
mRNA expression was observed. Interestingly, preventive treat-
ment with euphol (30 mg/kg) markedly inhibited the up-regulated
mRNA expression of ICAM-1, VCAM-1 and LFA-1 (Fig. 7) in
colonic tissue. In addition, to determine the effect of euphol in
regulating selectins, we performed immunofluorescence analysis of
colon samples obtained from mice after DSS-induced colitis.
Tissue sections from control healthy mice exhibited very low levels
of specific staining for P-selectin (Fig. 7D) and E-selectin (Fig. 7E)
in endothelial cells only. In contrast, 7 days after DSS
administration, intense immunostaining for both P- and E-selectin
expression in colon tissue was observed; however, preventive
treatment with euphol (30 mg/kg, p.o.) during the 7 days after
DSS administration resulted in a significant decrease in the
positive immunostaining for P- and E-selectin (Fig. 7 D,E).
Euphol treatment attenuates the severity of
TNBS-induced colitis
Recently, our group has shown that 72 h after TNBS
administration, mice developed severe diarrhea, striking hyper-
emia, necrosis and inflammation accompanied by an extensive
wasting disease, rectal prolapse and sustained weight loss [6]. To
assess whether or not euphol treatment would also prove to be
beneficial in another chemical model of colitis, we tested its effects
on some parameters of colitis induced by the hapten TNBS, which
constitutes a Crohn’s disease model. Rectal administration of
TNBS dissolved in ethanol induced severe colitis in CD1 mice that
was characterized by weight loss and diarrhea. Treatment with
euphol (30 mg/kg, p.o.), twice a day, starting 24 h after TNBS
administration (i.e., at a time point when colitis was already
established), significantly reduced body weight loss (Fig. 8A). At
this same dose, euphol also reduced the macroscopic damage score
(Fig. 8B) and the reduction in colon length (Fig. 8 C,D).
Discussion
Ulcerative colitis and Crohn’s disease are major forms of
inflammatory bowel disease (IBD), a disease that affects millions of
people worldwide and is characterized by chronic uncontrolled
Figure 4. Euphol reduces pro-inflammatory cytokines and chemokines production in macrophages stimulates with lipopolysac-
charide (LPS). Macrophage from bone marrow of naı ¨ve mice were stimulated with LPS (1 mg/ml) in the presence or absence of euphol (1 and
10 mM) for 24 hours, and the culture supernatants were analyzed for cytokine levels using cytokine bead array kit (CBA). Euphol incubation in dose-
related manner reduced production of MCP-1 (A), TNF-a (B), IL-6 (C), IFN-c (D), but increase the IL-10 levels (E). Data are reported as means 6 SEM
(n=4) and is representative of two independent experiments.
#P,0.05 vs. control without LPS treatment (vehicle solution); *P,0.05 vs. LPS-treated
group. Vehicle solution corresponds to 5% Tween 80 in medium.
doi:10.1371/journal.pone.0027122.g004
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interest, the pathogenesis of IBD still remains poorly understood;
the imbalance between pro-inflammatory cytokines, such as TNF-
a, IFN-c, IL-1b, IL-6 and IL-12, and anti-inflammatory cytokines,
such as IL-4, IL-10 and IL-11, is thought to play a pivotal role in
modulating gut inflammation [32]. It has been reported that these
inflammatory responses begin with a sudden infiltration of
neutrophils and macrophages [33] with the activated macrophages
producing a potent combination of broadly active inflammatory
cytokines, including TNF- a, IL-1 and IL-6 [34]. Conventional
therapy for IBD relies on the use of aminosalicylates, corticoste-
roids, immunosuppressive drugs and antibiotics [35]. Nowadays a
new class of drugs has been used for the treatment of IBD, among
them biologic agents such as anti-TNF therapy are noteworthy
[36,37]. However, these therapies for IBDs are usually associated
with several side effects or clinical limitations for use. Therefore,
there is a need for better therapeutic agents that effectively induce
remission and/or alter the natural course of the disease with
minimum or no side effects of treatment.
The use of medicinal plants or their active components is
becoming an increasingly attractive approach for the treatment of
various inflammatory disorders, such as rheumatoid arthritis
[38,39], multiple sclerosis {Ma, #622; Martin, #623; De Paula,
2008 #624} and ulcerative colitis [28]. Euphol, the alcohol
derivate tetracyclic triterpene is the main constituent found in the
sap of Euphorbia tirucalli, which is used as a folk therapy against
syphilis, asthma, rheumatism, cancer and sarcoma [17]. In
addition, a recent study have demonstrate that a biopolymeric
fraction (BET) obtained from E. tirucalli showed dose-dependent
anti-arthritic activity and demonstrated in vivo suppression of
CD4
+ and CD8
+ T cells associated with the inhibition of
intracellular IL-2 and IFN-c, and inhibited vascular permeability
Figure 5. Euphol treatment inhibits NOS2 and VEGF expression in colonic tissue. After a 7-day euphol treatment, colon samples were
processed for immunohistochemistry analysis. Preventive treatment with euphol (30 mg/kg, p.o.) significantly reduced NOS2 (A) and VEGF (B)
immunostaining in the colon tissue after DSS-induced colitis in mice. Graphical representation of the immunostaining for NOS2 (C) and VEGF (D)
expression evaluated in colon tissue. The mean intensity of NOS2 and VEGF staining were determined from image analysis and are represented as
optical density. Scale bar corresponds to 100 mm and applies throughout. Each column represents the mean 6 S.E.M. of 8 to 10 mice per group and is
representative of three independent experiments.
#P,0.05 vs. control healthy group (non colitic); *P,0.05 vs. DSS-treated group.
doi:10.1371/journal.pone.0027122.g005
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However, so far, there have been no reports about the effect of
euphol on inflammatory bowel disease, such as UC and CD. Our
results demonstrated the effectiveness of the isolated natural
tetracyclic triterpene euphol in ameliorating two experimental
model of colitis in mice. Euphol, given orally, consistently
ameliorated the inflammatory symptoms associated with DSS-
induced colitis, accompanied by a direct reduction in neutrophils
migration, overproduction of pro-inflammatory mediators, mac-
rophage infiltration and activation. Of interest, it was observed
that euphol produced a marked decrease in adhesion molecule
expression, such as integrins (ICAM-1, VCAM-1 and LFA-1) and
selectins (P- and E-selectins), without compromising the integrity
of the endothelial barrier, as seen by scanning electron
microscopy. In addition, the present study clearly showed that
euphol treatment consistently reduced activation of NOS-2,
VEGF, Ki67 and p65 NF-kB. Furthermore, we also demonstrated
that euphol treatment ameliorated TNBS-induced colitis, suggest-
ing that the anti-inflammatory effect of euphol did not depend on
the animal model of colitis used.
Several studies support a crucial role for neutrophils in
mediating tissue injury and clinical symptoms in colitis [7,8,43].
Here, DSS-mediated colitis induces MPO activity and relevantly
treatment with euphol prevented the increase in MPO activity.
The reduction in neutrophils influx after euphol treatment
observed in this study was associated with a decrease in colon
damage. Interestingly, euphol was able to modulate the release
and/or expression of pro-inflammatory cytokines/chemokines in
Figure 6. Euphol prevents inflammatory/enterocyte cells proliferation and NF-kB activation after DSS-induced colitis. Expression of
Ki67 and phosphorylation of NF-kB was performed 7 days after administration of DSS (3%) or with vehicle in colonic tissues. Pre-treatment with
euphol (30 mg/kg, p.o.), significantly inhibited proliferation index (Ki67) (A) and phosphorylation of p65 NF-kB (B) in colon tissue after DSS-induced
colitis in mice. (A–B) Representative images of Ki67 and phospho-p65 NF-kB immunoreactivity in colon tissue. Scale bar corresponds to 100 and
25 mm (black square) respectively, and applies throughout. Graphical representation of the immunostaining for Ki67 (C) and phospho-p65 NF-kB (D)
expression evaluated in colon tissue. The mean intensity of Ki67 and p65 NF-kB staining were determined from image analysis and are represented as
optical density. Each column represents the mean 6 S.E.M. of 8 to 10 mice per group and is representative of two independent experiments.
#P,0.05 vs. control healthy group (non colitic); *P,0.05 vs. DSS-treated group.
doi:10.1371/journal.pone.0027122.g006
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of experimental evidence indicating that cytokines, such as MIP-2
and CXCL1/KC, play a pivotal role in the regulation of cell
migration in colon tissue [6]. Taken together, these results suggest
that euphol treatment contributes to a decrease in cell influx by
diminishing the production of chemotactic factors, thus, in turn,
ameliorating colon inflammation.
As discussed earlier, given that inflammatory cells up-regulated
the production of cytokines/chemokines in pathological condi-
tions, we next investigated whether the decreased levels and/or
expression of colonic cytokines demonstrated by euphol treat-
ment could be just a consequence of decreased cell migration. To
further strengthen this view, we cultured primary bone marrow-
derived macrophages and showed that euphol significantly
reduced MCP-1, TNF-a, IL-6, and IFN-c production in
macrophages. Interestingly, in vitro pre-treatment (30 min) with
euphol (1 and 10 mM) markedly increased IL-10 production, a
relevant anti-inflammatory cytokine, in the macrophage culture
after LPS administration. Considering these data, it is possible to
suggest that euphol could modulate macrophage activation and
in consequence decrease cytokine production, an effect which
might contribute to the reduction of adhesion molecule
expression.
Nitrosative stress caused by nitric oxide synthase 2 (NOS2 or
iNOS)-derived nitric oxide (NO) is strongly associated with IBD
progression and contributes to the pathogenesis of human IBD
and experimental colitis [44]. Blocking NOS2 expression using
gene knockout or specific inhibitors ameliorates the severity of
experimental colitis [45,46]. In addition, another relevant study
has shown that NOS2 is implicated in the induction of VEGF
[25], a cytokine that has a relevant role in angiogenesis and is
increased in patients with IBD [26]. Additional evidence has
indicated that local microvasculature and inflammation-dependent
angiogenesis exert a relevant role in both human and murine IBD
[26,47,48]. Here, we demonstrated that induction of colitis was
associated with a significant increase in NOS2 and VEGF
Figure 7. Preventive treatment with euphol blocks integrins and selectins expression in the colonic tissue after DSS-induced colitis.
At the end of 7 days, colon tissue was collected and processed for mRNA expression and immunofluorescence. Preventive treatment with euphol
(30 mg/kg, p.o.) reduced colonic mRNA expression of inter-cellular adhesion molecule 1 (ICAM-1) (A), vascular cell adhesion molecule-1 (VCAM-1) (B)
and lymphocyte function-associated antigen 1 (LFA-1) (C). The real-time PCR assay was performed in duplicate and GAPDH mRNA was used to
normalize the relative amount of mRNA. The same scheme of treatment with euphol also impaired the increase of P-selectin (D) and E-selectin (E).
Representative images of P-selectin and E-selectin immunofluorescent stains were obtained on day 7 from control healthy mice, DSS-treated group
and euphol (30 mg/kg, p.o.) treated group. Nuclei were stained with Hoechst (0.5 ml/ml). Scale bar corresponds to 50 mm and applies throughout.
Data are reported as means 6 S.E.M. of 8 to 10 mice per group and is representative of three independent experiments.
#P,0.05 vs. control healthy
group (non colitic); *P,0.05 vs. DSS-treated group.
doi:10.1371/journal.pone.0027122.g007
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regulation after DSS-induced colitis, suggesting that blocking
intestinal inflammation and patho-angiogenesis through inhibiting
NOS2 and VEGF expression during IBD progression may be, at
least in part, the explanation of how euphol attenuates
experimental colonic inflammation.
In addition, the pathway underlying the euphol protection of
colon damage observed with preventive treatment could be
associated with diminished of inflammatory and enterocyte cells
proliferation (Ki67 immunostaining), which is a fundamental
protein involved in cell proliferation [27]. This event seems to be
associated with chronic inflammation and colon cancer and is
increased under this condition [49]. In the present study, oral
treatment with euphol notably reduced Ki67 protein activation
in colonic tissue, suggesting that euphol ameliorates acute colitis,
at least in parts, by reducing cell proliferation. However, these
events might be an indirect consequence of the general
improvement in inflammation mediated by euphol and need to
be further clarified.
Nuclear factor kB is a critical transcription factor involved in a
broad range of biological processes, including the regulation of
immune and inflammatory responses which has been associated to
the pathogenesis of colitis and other IBDs [50]. Activation of the
NF-kB transcription factor induces the expression of several pro-
inflammatory mediators, such as cytokines, chemokines and
adhesion molecules, which in turn mediate the recruitment and
activation of immune cells [51]. Herein, our results using the
phospho-p65 NF-kB antibody demonstrated that euphol is able to
inhibit the translocation of p65 into the nucleus, thus strongly
suggesting that inhibition of NF-kB activation should be a key
mechanism through which this natural tetracyclic triterpene
modulates intestinal inflammation.
An increasing body of evidence has emerged indicating that
cytokines and chemokines can up-regulate adhesion molecule
Figure 8. Therapeutic treatment with euphol protects mice against TNBS-induced acute colitis. Mice were given 100 mL of the TNBS (in
35% ethanol) and after 24 h, treated with euphol (30 mg/kg, p.o.). (A) The time-course of body weight changes on day 3 after TNBS-induced colitis. (B)
Macroscopic score; (C) colon length after TNBS-induced colitis. (D) Representative photograph of colons from day 3 after the induction of TNBS-colitis.
1, Control healthy mice; 2, TNBS-treated (only vehicle administration); 3, TNBS plus euphol (30 mg/kg, p.o.). Each column represents the mean 6
S.E.M. of 8 to 10 mice per group and is representative of two independent experiments.
#P,0.05 vs. control healthy group (non colitic); *P,0.05 vs.
TNBS-treated group. Vehicle corresponds to 5% Tween 80 in saline 0.9% NaCl.
doi:10.1371/journal.pone.0027122.g008
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leukocytes to extravasate from blood to the site of inflammation
caused by either exogenous or endogenous stimuli have been
recognized as the ‘three-step’ paradigm of inflammatory cell
recruitment that involve rolling, activation and adhesion [16]. The
interaction between leukocytes and the endothelium comprises a
variety of adhesive and migratory molecular events, including low
affinity transient and reversible rolling adhesion, integrin-depen-
dent firm adhesive interaction and migratory events of leukocytes
through the endothelium and beyond that, such as the penetration
of the membrane and migration into the interstitial space [16].
The initial process of active leukocyte recruitment is the tethering
or rolling of leukocytes, described as the initial selectin-mediated
interaction between leukocytes and endothelial cells [57].
Multiple studies have indicated that antibody blockade of
selectins inhibit leukocyte rolling in vivo [16], P-selectin
-/- mice
show no leukocyte rolling in vivo [58] and double knockout mice for
P- and E-selectin show a decrease in neutrophils mobilization [59].
The most important ligand for selectins is the P-selectin
glycoprotein ligand-1 (PSGL-1), which is present on leukocytes
and can bind to both P- and E-selectin [60]. Interestingly, PSGL-1
ligation in neutrophils by both P-selectin and E-selectin can result
in activation of integrins, thus providing a link between rolling and
the subsequent integrin-mediated firm adhesion [60]. Neutrophils
and macrophages both use lymphocyte function-associated
antigen 1 (LFA-1) (CD11a/CD18; aLb2) and Mac-l (CD11b/
CD18; aMb2) for adhesion [61] in endothelial ICAMs, such as
ICAM-1 and ICAM-2. Moreover, ICAM-1 expression is further
increased after endothelial activation [62], and neutrophils-
mediated adhesion to endothelial cells. In contrast, endothelial
VCAM-1 is recognized by b1-integrin receptors predominantly
found on lymphocytes and monocytes [63]. Another study
demonstrated that induction of colitis in rats by TNBS is followed
by up-regulation of endothelial VCAM-1, and suggests that
VCAM-1 and constitutive ICAM-1 are major determinants of
leukocyte recruitment to the inflamed intestine [64]. On the other
hand, a relevant report established that VCAM-1 plays a central
role in leukocyte recruitment in colitis and blockade of this
adhesion molecule has higher therapeutic effect than immune
neutralization of ICAM-1 or MAdCAM-1 in colitis experimental
model. In the same study, chronic administration of anti-VCAM-1
antibody, but not anti-ICAM-1 or anti-MAdCAM-1, resulted in
significant attenuation of colitis in terms of disease activity index,
colon length, ratio of colon weight to length, and myeloperoxidase
activity [65]. In this context, to gain further insight into the
mechanisms through which euphol modulates cell migration and
improves DSS-induced colitis in mice, we assessed the content of
chemotactic factors and the expression of adhesion molecules after
induction of colitis. Our results demonstrated that euphol almost
totally suppressed the increase in mRNA expression of all
integrins, accompanied by a significant decrease in the positive
immunostaining of both selectin in colon tissue. Our present data
suggest that euphol affects recruitment of leucocytes, especially
neutrophils and macrophages, by regulating adhesion molecule
expression in leucocytes and colonic endothelial cell. However, as
described above the anti-inflammatory effect of euphol in the
experimental colitis, could be justified mainly by the blockade of
VCAM expression in the colonic tissue, however further studies
are necessary to clarify this hypothesis.
In conclusion, our results demonstrate that orally-administered
euphol has both preventive and therapeutic anti-inflammatory
properties when assessed in two models of colitis in mice. The
beneficial action of euphol in ameliorating colitis seems likely
associated with its ability to prevent the expression of pro-
inflammatory mediators and/or release in colonic tissue through
inhibiting leukocyte influx (mainly neutrophils and macrophages)
into inflammatory foci by blocking adhesion molecule expression,
such as selectins (P- and E-selectins) and integrins (ICAM-1,
VCAM-1 and LFA-1), without compromising the integrity of the
endothelial barrier. Moreover, euphol treatment markedly inhib-
ited the activation of NF-kB in the mouse colon tissue. These
results suggest that euphol might constitute a potential candidate
for the treatment of IBD.
Materials and Methods
Experimental animals
Male CD1 mice (8–10 weeks of age) were obtained from the
Laborato ´rio de Farmacologia Experimental (LAFEX), Universi-
dade Federal de Santa Catarina (UFSC, Floriano ´polis, SC, Brazil)
and housed in collective cages at 22 6 1uC under a 12-h light/
dark cycle (lights on at 07:00 h), with free access to food and tap
water. All experiments were performed during the light phase of
the cycle. The experimental procedures were previously approved
by UFSC’s Committee on the Ethical Use of Animals and were
carried out in accordance with Brazilian regulations on animal
welfare (CEUA/UFSC protocol number 23080.030926/2010-62).
DSS-induced colitis
This model of colitis was employed as previously described [66]
and consisted of adding 3% w/v dextran sodium sulfate (30–
50 kD, MP Biomedicals, Cleveland, OH, USA) to the animals’
drinking water for 5 days, followed by another 2 days during
which they were offered DSS-free (i.e., plain) drinking water alone.
Control healthy mice (non colitic) received plain drinking water at
all times.
TNBS-induced colitis
This colitis model employed here was originally described [67]
and slightly modified [6]. After being deprived of food for 18–24 h
with free access to a 5% glucose solution, mice were randomly
divided into control healthy and colitis groups. Briefly, mice
deprived of food for 1 day were lightly anaesthetized by
administration of xylazine (10 mg/kg, i.p.) and ketamine
(80 mg/kg, i.p.), and then a catheter (polyethylene PE-50) was
carefully inserted into the colon (4 cm proximal to the anus). To
induce colitis, TNBS (1.5 mg in 100 mL of 35% ethanol solution)
was slowly administered (day 0). To assure the distribution of
TNBS within the entire colon, mice were carefully maintained at a
45u angle (head down position) for 2 min and then returned to
their cages. Four hours later, the animals were given free access to
food and water. Throughout the experiments, mice were
monitored for body weight loss and overall mortality. At 72 h
following TNBS administration (day 3), i.e., 4 h after receiving the
last injection, the animals were killed, and the colon was removed,
dissected and opened lengthwise.
Treatment protocols
The compound euphol was diluted in 5% Tween 80 solution
made in saline (0.9% NaCl solution) and administered orally by
gavage (p.o.). In the experiments involving DSS-induced colitis,
mice received euphol (3, 10 and 30 mg/kg, p.o.) or vehicle (5%
Tween 80 in saline 0.9% NaCl) twice a day from day 0 to day 7
(preventive treatment) or with 30 mg/kg from day 3 to day 7
(therapeutic treatment), and were sacrificed 4 h after receiving the
last administration. After that the dose of 30 mg/kg (p.o.) euphol
was used in subsequent experiments. To evaluate the potential
therapeutic effect of euphol in TNBS-induced colitis, animals were
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the corresponding vehicle (5% Tween 80 in saline 0.9% NaCl),
starting 24 h after TNBS instillation (day 1) during 3 consecutive
days (day 1–3). Vehicle solution (5% Tween 80 in 0.9% NaCl
solution) was used in control experiments. The dose of each drug
was chosen based on preliminary studies.
Body weight change and disease activity index
Body weight was measured daily, starting on the day preceding
DSS administration and up to 7 days thereafter in the DSS model.
Body weight was also measured daily in the TNBS model, starting
on the day preceding colitis induction (i.e., before fasting) and then
again justprior tointracolonicTNBSor vehicle administration (after
fasting) and up to 72 h after treatment. In the DSS model only, the
clinical disease activity index (DAI) was measured daily using the
protocol previously described [68], which ranged from 0 to 4 and
was the sum of scores given for body weight loss (scored as: 0, none;
1, 1–5%; 2, 5–10%; 3, 10–20%; 4, over 20%), stool consistency
(scored as: 0, well formed pellets; 2, loose stools; 4, diarrhea) and
presence or absence of fecal blood (scored as: 0, negative hemoccult
test; 2, positive hemoccult test; 4, gross bleeding).
Macroscopic and microscopic colonic damage
In the DSS model at the end of the 7-day period, colons were
removed and examined for: weight, the consistency of the stool
found within as well as gross macroscopic appearance and length,
which was measured from 1 cm above the anus to the top of the
cecum. Macroscopic damage was assessed according previously
[69], as the sum of scores attributed to stool condition (0, normal
well-formed fecal pellets; 1, loosely shaped moist pellets; 2,
amorphous, moist, sticky pellets; 3, diarrhea; plus 1 for presence
of blood in stool), colon damage (0, no inflammation; 1, reddening,
mild inflammation; 2, moderate or more widely distributed
inflammation; 3, severe and/or extensively distributed inflamma-
tion), colon weightloss (0,for ,5%;1, for 5–14%;2, for 15–24%; 3,
for 25–35%;4,for .35%) andcolon length shortening(0,for ,5%;
1, for 5–14%; 2, for 15–24%; 3, for 25–35%; 4, for .35%), with up
to a maximum total score of 15. To evaluate microscopic colon
damage by light microscopy, samples of the distal colon were fixed
immediately in 10% formaldehyde solution, embedded in paraffin,
cut into 5 mm thick transversal sections, mounted on glass slides,
deparaffinized and stained with hematoxylin and eosin stain (H&E).
In each specimen, six random fields of view were analyzed by two
double-blind observers, using Sight DS-5M-L1 digital camera
connected to an Eclipse 50i light microscope (both from Nikon,
Melville, NY, USA). The intensity of microscopic colonic damage
wasassessed accordingtothescoring systemdescribedbyRathetal.
[70] and modified by Van der Sluis et al. [71].
In the TNBS model, at 3 days after TNBS administration, mice
weresacrificed and their colonsremoved and rinsedwithsaline,and
macroscopic colonic damage was evaluated using the following
scoring system: 0, no damage; 1, hyperemia without ulcers; 2,
hyperemia with bowel wall thickening but no ulcers; 3, one site of
ulceration without bowel wall thickening; 4, two or more sites of
ulceration or inflammation; 5, 0.5 cm of inflammation and major
damage; 6, at least 1 cm of major damage (for every additional
0.5 cm of damage, the score was increased by one to a maximum of
10); plus 1 for presence of diarrhea or stricture; plus 1 or 2 for
presence of mild or severe adhesions, respectively [72].
Scanning electron microscopy (SEM)
SEM was used to visualize topographical alterations of the
luminal surface of the colon from control healthy, untreated and
treated mice. Fragments of 2 mm thickness from the mid-colon
were pre-fixed in the field in 2.5% glutaraldehyde in 0.1M sodium
phosphate buffer (pH 7.4) and kept on ice. The specimens were
then rinsed in the same buffer, post-fixed in 2% osmium tetroxide
(OsO4) for 4 h, dehydrated in a graded ethanol series (30% to
100%) and dried in hexamethyldisilazane (HMDS). The samples
were glued onto stubs, covered with gold particles (Bio-Rad
SC502, Hertfordshire, UK) and observed under a scanning
electron microscope (JEOL JSM-6390LV, Tokyo, Japan).
Myeloperoxidase assay
Neutrophil infiltration into the colon was assessed indirectly by
measuring myeloperoxidase (MPO) activity. Mid-colon segments
were homogenized in ethylenediaminetetraacetic acid (EDTA)/
NaCl buffer (pH 4.7) and centrifuged at 10,000 rpm for 15 min at
4uC. The pellet was ressuspended in 0.5% hexadecyltrimethyl
ammonium bromide buffer (pH 5.4) and frozen in liquid nitrogen
and thawed repeatedly three times. Samples were then centrifuged
again (10,000 rpm, 15 min, 4uC) and 25 ml of the supernatant was
used for the MPO assay. The enzymatic reaction was assessed by
the addition of 25 ml of 1.6 mM tetramethylbenzidine (TMB) in
80 mM NaPO4, plus 100 ml of 0.3 mM H2O2. MPO activity was
measured spectrophotometrically at 650 nm and the results are
expressed as optical density (OD) per milligram of tissue.
Determination of cytokine levels
Mid-colon segments were homogenized in phosphate buffer
containing 0.05% Tween 20, 0.1 mM phenylmethylsulfonyl
fluoride, 0.1 mM benzethonium chloride, 10 mM EDTA and
20 IU aprotinin A. The homogenates were centrifuged at 3,0006g
for 10 min and the supernatants stored at 280uC until assays for
the determination of levels of the cytokines IL-1b, keratinocyte-
derived chemokine (CXCL1/KC), monocyte chemoattractant
protein-1 (MCP-1) and macrophage-inflammatory protein-2
(MIP-2) were carried out. The amount of protein in each sample
was measured using the Bradford method [73], using bovine
serum albumin as a standard. The levels of each cytokine were
evaluated using enzyme-linked immunosorbent assay (ELISA) kits
according to the manufacturer’s recommendations (R&D systems,
Minneapolis, MN, USA) and the results are expressed in pg/mg of
protein in each sample.
Real-time quantitative PCR
Total RNA was extracted from mid-colon samples taken from
anesthetized mice treated with DSS using the Trizol protocol
(Invitrogen, Carlsbad, CA, USA) and its concentration was
determined by NanoDrop
TM 1100 (NanoDrop Technologies,
Wilmington, DE, USA). A reverse transcription assay was
performed as described in the M-MLV Reverse Transcriptase
protocol according to the manufacturer’s instructions. cDNA
(300 ng) was amplified in triplicate using TaqManH Universal
PCR Master Mix Kit with specific TaqMan Gene Expression target
genes, the 3’ quencher MGB and FAM-labeled probes for mouse
TNF-a (Mm00443258_m1), IL-1b (Mm01336189_m1), CXCL1/
KC (Mm00433859_m1), IL-6 (Mm99999064_m1), ICAM-1
(Mm005616024_g1), VCAM-1 (Mm01320970_m1), lymphocyte
function- associated antigen 1 (LFA-1, Mm01278854_m1) and
GAPDH (NM_008084.2) (which was used as an endogenous
control for normalization). The PCR reactions were performed in a
96-well Optical Reaction Plate (Applied Biosystems, Foster City,
CA, USA). The thermocycler parameters were as follows: 50uC for
2 min, 95uC for 10 min, 50 cycles of 95uC for 15 sec and 60uC for
1 min. Expression of the target genes was calibrated against
conditions found in control non-colitic animals, i.e., those that
received vehicle (5% Tween 80 in saline 0.9% NaCl).
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Seven days after DSS-induced experimental colitis, animals
were sacrificed and each portion of the distal colon was fixed
immediately in 4% paraformaldehyde in 0.1 M phosphate buffer
(pH 7.4). Colons were removed and post-fixed 24 h in the same
solution, following embedding in paraffin and sections (5 mm)
mounted on glass slide and deparaffinized. Immunohistochemical
analysis was performed on paraffin-embedded colon tissue (5 mm)
using polyclonal rabbit anti-NOS2 (1:300), monoclonal mouse
anti-VEGF (1:300), polyclonal rabbit anti-Ki-67 (1:300) and
monoclonal mouse anti-phospho-p65 NFkB (1:50) according to
the method described previously [74]. After quenching of
endogenous peroxidase with 1.5% hydrogen peroxide in methanol
(v/v) for 20 min, high-temperature antigen retrieval was per-
formed by immersion of the slides in a water bath at 95 to 98uCi n
10 mmol/L trisodium citrate buffer, pH 6.0, for 45 min. The
slides were then processed using the VECTASTAINH Elite ABC
reagent (Vector Laboratories, Burlingame, CA), according to the
manufacturer’s instructions. After the appropriate biotinylated
secondary antibody, sections were developed with 3,3’-diamino-
benzidine (Dako Cytomation, Glostrup, Denmark) in chromogen
solution for the exact same amount of time and counterstained
with Harris’s hematoxylin. For immunofluorescence, sections
5 mm in thickness were deparaffinized and blocked with 2%
BSA in 0.3% Triton X-100 for 1 h at room temperature and
incubated overnight at 4uC with antibodies specific for P-selectin
(polyclonal goat; 1:200 dilution) and E-selectin (polyclonal goat;
1:100 dilution), followed by fluorescein isothiocyanate-conjugated
donkey goat-specific secondary antibody (1:50 dilution; Vector
Laboratories, Burlingame, CA) for 2 h at room temperature.
Nuclei were stained with Hoechst (0.5 ml/ml; Molecular Probes).
Images were acquired using a Sight DS-5M-L1 digital camera
connected to Eclipse 50i light microscope fluorescence (both from
Nikon, Melville, NY, USA). Four ocular fields per section (5–10
mice per group) were captured and a threshold optical density that
best discriminated staining from the background was obtained
using the NIH ImageJ 1.36b imaging software (NIH, Bethesda,
MD, USA). For immunohistochemistry analysis, total pixel
intensity was determined and data are expressed as optical density
(OD). For immunofluorescence, signal intensities were collected in
triplicate and microscopy data were acquired by two investigators
‘blinded’ to the identity of the disease group.
Murine bone marrow-derived macrophages
CD1 mice were sacrificed by cervical dislocation. Total bone
marrow was obtained from mice by flushing the femurs and tibiae
with Dulbecco modified eagle medium (DMEM), as previously
described [75]. Briefly, bone marrow mononuclear phagocyte
precursor cells were propagated in suspension by culturing in
macrophage medium (DMEM containing glucose, supplemented
with 2 mM L-glutamine, 10% FCS, 10 mM Hepes, 100 mg/ml
streptomycin, 100 U/ml penicillin (all from Sigma-Aldrich) sup-
plemented with 20% L929 cell-conditioned medium (as a source of
M-CSF). Cells were incubated at 37uCi n5 %C O 2 air and fed on
day 5 by replacing the medium supplemented with 20% L929 cell-
conditioned medium. Cells were harvested on day 7, and
1610
6 cells/ml were cultured in a 96-well cell culture plate for
24 h. Afterwards, adherent cells were stimulated for 24 h with LPS
(1 mg/ml) in the presence or absence of euphol (1 and 10 mM) in a
final volume of 250 ml/well. Control group corresponds to 5%
Tween 80 in medium with/without LPS treatment. After
stimulation, the plate was centrifuged (2006g/10 min) and the
cell-freesupernatantwascollectedandstored at270uC forcytokine
determination. A cytokine bead array Mouse Kit Inflammation was
used to measure MCP-1, TNF-a, IL-6, IFN-c and IL-10 secretion
in the supernatant. The data were acquired using BD FACSCanto
II(BD Biosciences,SanDiego,CA,USA) and analyzed usingFCAP
Array software (BD Biosciences, San Diego, CA, USA).
Drugs and reagents
The sap from Euphorbia tirucalli was initially extracted with
hexane and the resulting precipitate was extracted with n-butanol.
The most lipophilic compounds present in the methanol fraction
were purified by means of high performance liquid chromatog-
raphy (HPLC) analysis. Further purification of the compounds was
carried using Sephadex G-75 in a mixture of hexane-ethyl acetate.
The euphol chemical characterization was conducted by means of
nuclear magnetic resonance (NMR) and mass spectroscopic data.
The tetracyclic triterpene euphol used in this study showed a
purity .95%. Dexamethasone, H2O2, Tween 20, Tween 80,
EDTA, aprotinin, phosphate buffered saline (PBS), H&E, 3,3,5,5-
tetramethylbenzidine, H2O2 and TNBS were purchased from
Sigma Chemical Co. (St. Louis, MO, USA). Formaldehyde was
obtained from Merck (Frankfurt, Darmstadt, Germany). Anti
mouse-KC and the DuoSet kits for IL-1b/IL-1F2, MCP-1 and
MIP-2 were obtained from R&D Systems (Minneapolis, MN,
USA). Bradford reagent was purchased from Bio-Rad Laborato-
ries (Richmond, CA, USA). Polyclonal rabbit anti-NOS2 was
purchased from Thermo Fisher Scientific Inc. (Fremont, CA,
USA). Monoclonal mouse anti-VEGF was purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal mouse
anti-phospho-p65 NF-kB was purchased from Cell Signaling
Technology (Danvers, MA, USA) and polyclonal rabbit anti-Ki-67
from purchased Abcam (Cambridge, MA, USA). Secondary
antibody Envision Plus, streptavidin–HRP reagent, and 3,3-
diaminobenzidine chromogen were purchased from DakoCyto-
mation (Carpinteria, CA, USA). Trizol and M-MLV reverse
transcriptase were purchased from Invitrogen (Carlsbad, CA,
USA). Primers and probes for mouse TNF-a (Mm00443258_m1),
IL-1b (Mm01336189_m1), CXCL1/KC (Mm00433859_m1), IL-
6 (Mm99999064_m1), ICAM-1 (Mm005616024_g1), VCAM-1
(Mm01320970_m1), LFA-1 (Mm01278854_m1), GAPDH
(NM_008084.2) and TaqManH Universal PCR Master Mix Kit
were purchased from Applied Biosystems (Foster City, CA, USA).
The CBA Mouse Inflammation Kit was purchased from BD
Biosciences (San Diego, CA, USA). The compound euphol (3, 10
and 30 mg/kg) was diluted in a 5% Tween 80 solution made in
saline (0.9% NaCl solution) and administered orally by gavage
(p.o.). All other drugs were made in physiological saline (0.9%
NaCl solution).
Statistical analysis
All data were expressed as means 6 S.E.M. (n=8210 animals/
group). Statistical analysis was performed using Kruskal-Wallis
followed by Dunn’s test for non-parametric data, one-way
ANOVA followed by Newman-Keuls test for parametric data.
All analysis was conducted using GraphPad Prism 4 software
(GraphPad Software Inc., San Diego, CA, USA). Differences with
p#0.05 were considered to be statistically significant.
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